Top Story Today
J&J Killed a CAR-T Program With 100% Response Rates. The Reason Is Scarier Than Any Failed Trial.
Johnson & Johnson halted its CD20 mono and CD19-CD20 bi-CAR-T lymphoma programs despite Phase 1b data showing 100% response rates and zero severe side effects at the recommended dose. No safety disaster, no efficacy miss; just a cold-blooded business decision. The real culprit is CAR-T economics: manufacturing costs run $100K to $200K per dose, total patient costs can hit $2 million, and standard Medicare reimbursement runs around $269K–$314K per case. With four entrenched competitors in B-cell lymphoma, J&J chose to consolidate around Carvykti (its myeloma blockbuster) rather than fight for parking in a crowded lot.
Why it matters: This signals a new era where stellar clinical data alone can't justify a CAR-T program. Manufacturing scale and reimbursement math are now the real moats, and late entrants to crowded indications face near-impossible commercial headwinds regardless of efficacy.
Read more →Clinical & Regulatory
FDA Panel Votes 6-3 Against AstraZeneca's Early-Switch Breast Cancer Strategy
An FDA advisory committee rejected AstraZeneca's camizestrant, which proposed switching breast cancer patients to a new drug the moment a blood test detects resistance mutations, before the cancer visibly worsens. The panel's core objection: the trial proved switching beats never switching, but never compared early switching to switching at normal progression. It's a warning shot for the entire field of biomarker-driven preemptive therapy.
Read more →The HIV Drug the FDA Killed in 2021 Just Got Approved
Merck's islatravir was slapped with a clinical hold across 13 trials in 2021 after tanking patients' immune cells. Four years later, a lower dose paired with doravirine earned FDA approval as Idvynso, a two-drug HIV pill that matched Biktarvy's efficacy with a manageable safety profile. It's the first oral regimen avoiding both integrase inhibitors and tenofovir.
Read more →FDA Approves First Oral Small-Molecule GLP-1 for Obesity
Eli Lilly's Foundayo (orforglipron) is now the first small-molecule GLP-1 pill approved for weight management, no food restrictions, no injection training required. It delivered 12.4% body weight loss in trials. Self-pay pricing starts at $149 per month, and Lilly is targeting the large share of eligible patients who have avoided injectable GLP-1s.
Read more →Pipeline Setbacks
Amgen Loses Two Programs in One Week to Phase 2 Failures
Amgen's Sjogren's disease candidate AMG 329 hit pre-defined futility criteria (the clinical trial equivalent of your coach calling the game at halftime), and its AMG 193 cancer combination with Ideaya was terminated after underwhelming data. Neither loss is existential for a $37B revenue company, but both narrow the pipeline at a competitive moment.
Read more →Indivior Guts R&D Team After Opioid Addiction Drug Flops
Indivior's INDV-2000, designed to block the brain's craving circuitry for opioid addiction, couldn't beat placebo in Phase 2. The company is now slashing its research team and pivoting to a single-product commercial model around SUBLOCADE, which grew 32% to $232M in Q1. The stock rose 9.6% anyway. Wall Street loves focus; pipeline depth is tomorrow's problem.
Read more →Deals & Discovery
BMS Ends 11-Year Bispecific Antibody Deal With Zymeworks
Bristol Myers Squibb terminated its Celgene-era collaboration with Zymeworks, killing a Phase 1 bispecific cancer program inherited from BMS's $74 billion acquisition. The irony: BMS simultaneously paid $11.1 billion for a BioNTech bispecific last year. Big pharma wants bispecifics, just not early-stage ones from old deals.
Read more →LEO Pharma Pays $50M to Turn Herpes Into a Skin Disease Cure
Danish dermatology company LEO Pharma acquired Replay, which engineered herpes simplex virus into a gene therapy delivery vehicle for devastating skin diseases like dystrophic epidermolysis bullosa. The delivery method is a topical gel (not an injection), patients can be redosed, and the virus naturally targets skin cells. Still preclinical, but the biology is already validated by an approved competitor.
Read more →